{"mainPropery":{"diseaseId":8618,"diseaseName":"Primary myelofibrosis","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/8618/primary-myelofibrosis","synonyms":["Idiopathic myelofibrosis","Myeloid metaplasia","Agnogenic myeloid metaplasia"],"synonyms-with-source":[{"name":"Idiopathic myelofibrosis"},{"name":"Myeloid metaplasia"},{"name":"Agnogenic myeloid metaplasia"}],"identifiers":[{"identifierType":"OMIM","identifierId":"254450"},{"identifierType":"ORPHANET","identifierId":"824"}]},"diseaseCategories":[{"diseaseTypeId":12,"diseaseTypeName":"Blood Diseases","source":"Orphanet"},{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":426,"resourceName":"MPN Research Foundation","abbreviation":"","address1":"180 N. Michigan Avenue","address2":"Suite 1870","address3":"","address4":"","address5":"","city":"Chicago","state":"IL","zip":"60601","country":"United States","phone":"+1-312-683-7249","tty":"","tollFree":"+1-855-258-1943 (Support)","fax":"+1-312-332-0840 ","email":"rrosen@MPNResearchFoundation.org","url":"http://www.mpnresearchfoundation.org/","freeText":""},{"resourceID":570,"resourceName":"Leukemia and Lymphoma Society","abbreviation":"","address1":"3 International Drive, Suite 200","address2":"","address3":"","address4":"","address5":"","city":"Rye Brook","state":"NY","zip":"10573","country":"United States","phone":"1-(888) 557-7177 (general)","tty":"","tollFree":"1-(800) 955-4572 (patients and families)","fax":"","email":"https://www.lls.org/content/contact-us","url":"https://www.lls.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/254450' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=myelofibrosis%5BTitle%5D+AND+%28hasabstract%5Btext%5D+AND+%222004%2F01%2F10%22%5BPDat%5D+%3A+%222009%2F01%2F07%22%5BPDat%5D+AND+Review%5Bptyp%5D%29' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Primary myelofibrosis. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Myelofibrosis%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Primary myelofibrosis. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition/primary-myelofibrosis' target='_blank'>MedlinePlus Genetics</a> contains information on Primary myelofibrosis. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":762,"resourceId":1447,"resourceName":"Myelofibrosis","descriptionText":"The <a href='http://www.lls.org/myeloproliferative-neoplasms/myelofibrosis' target='_blank'>Leukemia &amp; Lymphoma Society</a> has an article on idiopathic myelofibrosis. Click on Leukemia &amp; Lymphoma Society to view the article.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":955,"resourceId":1652,"resourceName":"Myeloproliferative Disease Support and Daily Email Digest","descriptionText":"<a href='http://mpdsupport.org/ ' target='_blank'>MPD-Support</a>: Myeloproliferative Diseases Support and Daily E-mail Digest","resourceClassificationName":"Organizations","resourceClassificationSectionName":"Social Networking Websites"},{"id":982,"resourceId":1677,"resourceName":"MPD-RC Myeloproliferative Disorders Research Consortium","descriptionText":"The&nbsp;<a href='https://mpdrc.org/home.php ' target='_blank'>Myeloproliferative DisordersÂ Research Consortium (MPD-RC)</a> is an international, multi-institutional non-profit consortium funded by the National Cancer Institute (NCI) at the National Institutes of Health and set up to coordinate, facilitate, and perform basic and clinic research investigating the genetics of MPDs with the goal of developing therapy. To learn more, click on the link.","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":999,"resourceId":1860,"resourceName":"Mayo Clinic","descriptionText":"<a href='https://www.mayoclinic.org/diseases-conditions/myelofibrosis/symptoms-causes/syc-20355057' target='_blank'>MayoClinic.com</a> offers additional information about myelofibrosis. Click on the above link to access this information.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/CN034362' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/244/viewAbstract' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/000531.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/956806-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=824' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1756,"resourceId":2916,"resourceName":"NORD Physician Guide","descriptionText":"The <a href='https://rarediseases.org/physician-guide/myleofibrosis/' target='_blank'>NORD Physician Guide</a> for Primary myelofibrosis was developed as a free service of the National Organization for Rare Disorders (NORD) and it's medical advisors. &nbsp;The guides provide a resource for clinicians about specific rare disorders to facilitate diagnosis and treatment of their patients with this condition.&nbsp;","resourceClassificationName":"Treatment","resourceClassificationSectionName":"Management Guidelines"},{"id":1830,"resourceId":1676,"resourceName":"MPN Education Foundation","descriptionText":"The&nbsp;<a href='http://mpninfo.org/mf' target='_blank'>MPN Education Foundation</a> provides information on&nbsp;Primary myelofibrosis.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:254450' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2160,"resourceId":3368,"resourceName":"Patient Access Network Foundation","descriptionText":"<a href='https://panfoundation.org/index.php/en/patients/assistance-programs/myelodysplastic-syndromes' target='_blank'>Patient Access Network Foundation</a> (PAN Foundation) has Assistance Programs for those with health insurance who reside in the United States. The disease fund status can change over time, so you may need to check back if funds are not currently available.&nbsp;","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2163,"resourceId":3372,"resourceName":"Good Days","descriptionText":"<a href='https://www.mygooddays.org/patients/diseases-covered/chronic-iron-overload' target='_blank'>Good Days</a> provides help to patients with life-altering conditions. Assistance includes help with the cost of medications and travel.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":1495,"questionText":"What is primary myelofibrosis?","answerText":"<strong>Primary myelofibrosis</strong> is a condition characterized by the buildup of scar tissue (fibrosis) in the spongy tissue tissue inside the bone (bone marrow), the tissue that contains the stem cells that will produce blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. In myelofibrosis, the bone marrow is replaced by fibrous (scar) tissue.[880][11748]&nbsp; When the bone marrow is scarred, it cannot make enough blood cells. This leads to&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/anemia.html\" target=\"_blank\">anemia</a>, weakness, fatigue, and often, swelling of the liver and spleen.[880][881] The disorder occurs when blood stem cells develop&nbsp;<a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=46586\" target=\"_blank\">somatic mutations</a>&nbsp;in the&nbsp;<em><a href=\"https://ghr.nlm.nih.gov/gene/JAK2\" target=\"_blank\">JAK2</a>, <a href=\"https://ghr.nlm.nih.gov/gene/MPL\" target=\"_blank\">MPL</a>, <a href=\"https://ghr.nlm.nih.gov/gene/CALR\" target=\"_blank\">CALR</a>, </em>and<em> <a href=\"https://ghr.nlm.nih.gov/gene/TET2\" target=\"_blank\">TET2</a> </em>genes. Other genes may also be involved. The disorder is generally not inherited&nbsp;<span style=\"font-size: 12pt;\">because this type of </span><span style=\"font-size: 12pt;\">mutation</span><span style=\"font-size: 12pt;\"> does not affect the reproductive cells (sperm and egg) only certain cells of the body (somatic).[11748]&nbsp;</span>Although myelofibrosis can&nbsp;occur at any age, it typically develops after the age of 50 years.[880][881]&nbsp;In most cases, myelofibrosis gets progressively worse. Treatment&nbsp;is aimed at&nbsp;relieving signs and symptoms and may include medications, blood transfusions, chemotherapy, radiation therapy, and surgery.[881]&nbsp;<a id=\"anch_34\" href=\"https://medlineplus.gov/ency/article/003009.htm\" test=\"test\">Bone marrow</a> or stem cell transplant may improve symptoms, and may cure the disease.[880] &nbsp;&nbsp;","dateModified":"2017-06-13T00:00:00"},"basicQuestions":[{"questionId":1496,"questionText":"How rare is myelofibrosis?","answerText":"Few epidemiologic studies are available to estimate the occurrence of myelofibrosis.[882] Through the review of several medical textbooks and journal articles, it appears as if the annual incidence (occurrence) in European, Australian, and North American populations ranges from 0.3 to 1.5 cases per 100,000 persons.[882][883][884][11742][11743]","dateModified":"2016-06-22T00:00:00","resourceClassificationName":"Statistics","references":[{"referenceId":882,"authors":"Hoffman R, Ravandi-Kashani F","articleTitle":"Chapter 70 - Idiopathic Myelofibrosis","bookWebsiteJournalTitle":"Hematology: Basic Principles and Practice, 4th edition","date":"2005","authors2":"","placeOfPublication":"Philadelphia, PA","publisher":"Elsevier"},{"referenceId":883,"authors":"Tefferi, A","articleTitle":"Chapter 177 - Myeloproliferative Disorders: Essential Thrombocytopenia and Primary Myelofibrosis","bookWebsiteJournalTitle":"Cecil Medicine, 23rd edition","date":"2007","authors2":"","placeOfPublication":"Philadelphia, PA","publisher":"Elsevier"},{"referenceId":884,"authors":"Tefferi A","articleTitle":"Chapter 106- Myeloproliferative Disorders","bookWebsiteJournalTitle":"Abeloff's Clinical Oncology, 4th edition","date":"2008","authors2":"","placeOfPublication":"Philadelphia, PA","publisher":"Elsevier"},{"referenceId":11742,"authors":"Mehta J, Wang H, Iqbal SU, Mesa R.","articleTitle":"Epidemiology of myeloproliferative neoplasms in the United States","bookWebsiteJournalTitle":"Leuk. Lymphoma","date":"March 1, 2014","volume":"55(3)","pages":"595-600","url":"http://www.ncbi.nlm.nih.gov/pubmed/23768070","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11743,"authors":"Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA.","articleTitle":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","bookWebsiteJournalTitle":"Eur. J. Haematol.","date":"April 1, 2014","volume":"92(4)","pages":"289-297","url":"http://www.ncbi.nlm.nih.gov/pubmed/24372927","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":9319,"relatedDiseaseName":"Chronic myeloproliferative disorders","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[{"caseId":22942,"abbreviatedInquiry":"I need to ascertain the&nbsp;incidence of myelofibrosis in the United States. Is myelofibrosis considered to be a rare disorder?","caseQuestions":[{"questionId":1495,"questionText":"What is primary myelofibrosis?","answerText":"<strong>Primary myelofibrosis</strong> is a condition characterized by the buildup of scar tissue (fibrosis) in the spongy tissue tissue inside the bone (bone marrow), the tissue that contains the stem cells that will produce blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. In myelofibrosis, the bone marrow is replaced by fibrous (scar) tissue.[880][11748]&nbsp; When the bone marrow is scarred, it cannot make enough blood cells. This leads to&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/anemia.html\" target=\"_blank\">anemia</a>, weakness, fatigue, and often, swelling of the liver and spleen.[880][881] The disorder occurs when blood stem cells develop&nbsp;<a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=46586\" target=\"_blank\">somatic mutations</a>&nbsp;in the&nbsp;<em><a href=\"https://ghr.nlm.nih.gov/gene/JAK2\" target=\"_blank\">JAK2</a>, <a href=\"https://ghr.nlm.nih.gov/gene/MPL\" target=\"_blank\">MPL</a>, <a href=\"https://ghr.nlm.nih.gov/gene/CALR\" target=\"_blank\">CALR</a>, </em>and<em> <a href=\"https://ghr.nlm.nih.gov/gene/TET2\" target=\"_blank\">TET2</a> </em>genes. Other genes may also be involved. The disorder is generally not inherited&nbsp;<span style=\"font-size: 12pt;\">because this type of </span><span style=\"font-size: 12pt;\">mutation</span><span style=\"font-size: 12pt;\"> does not affect the reproductive cells (sperm and egg) only certain cells of the body (somatic).[11748]&nbsp;</span>Although myelofibrosis can&nbsp;occur at any age, it typically develops after the age of 50 years.[880][881]&nbsp;In most cases, myelofibrosis gets progressively worse. Treatment&nbsp;is aimed at&nbsp;relieving signs and symptoms and may include medications, blood transfusions, chemotherapy, radiation therapy, and surgery.[881]&nbsp;<a id=\"anch_34\" href=\"https://medlineplus.gov/ency/article/003009.htm\" test=\"test\">Bone marrow</a> or stem cell transplant may improve symptoms, and may cure the disease.[880] &nbsp;&nbsp;","dateModified":"2017-06-13T00:00:00","references":[{"referenceId":880,"authors":"Chen YB","articleTitle":"Myelofibrosis","bookWebsiteJournalTitle":"MedlinePlus","date":"May 29, 2014","volume":"","pages":"","url":"http://www.nlm.nih.gov/medlineplus/ency/article/000531.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":881,"authors":"","articleTitle":"Myelofibrosis","bookWebsiteJournalTitle":"MayoClinic.com","date":"August 1, 2014","volume":"","pages":"","url":"https://www.mayoclinic.org/diseases-conditions/myelofibrosis/symptoms-causes/syc-20355057","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11748,"authors":"","articleTitle":"Primary myelofibrosis","bookWebsiteJournalTitle":"Genetics Home Reference (GHR)","date":"September 2014","volume":"","pages":"","url":"https://ghr.nlm.nih.gov/condition/primary-myelofibrosis","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1496,"questionText":"How rare is myelofibrosis?","answerText":"Few epidemiologic studies are available to estimate the occurrence of myelofibrosis.[882] Through the review of several medical textbooks and journal articles, it appears as if the annual incidence (occurrence) in European, Australian, and North American populations ranges from 0.3 to 1.5 cases per 100,000 persons.[882][883][884][11742][11743]","dateModified":"2016-06-22T00:00:00","resourceClassificationName":"Statistics","references":[{"referenceId":882,"authors":"Hoffman R, Ravandi-Kashani F","articleTitle":"Chapter 70 - Idiopathic Myelofibrosis","bookWebsiteJournalTitle":"Hematology: Basic Principles and Practice, 4th edition","date":"2005","authors2":"","placeOfPublication":"Philadelphia, PA","publisher":"Elsevier"},{"referenceId":883,"authors":"Tefferi, A","articleTitle":"Chapter 177 - Myeloproliferative Disorders: Essential Thrombocytopenia and Primary Myelofibrosis","bookWebsiteJournalTitle":"Cecil Medicine, 23rd edition","date":"2007","authors2":"","placeOfPublication":"Philadelphia, PA","publisher":"Elsevier"},{"referenceId":884,"authors":"Tefferi A","articleTitle":"Chapter 106- Myeloproliferative Disorders","bookWebsiteJournalTitle":"Abeloff's Clinical Oncology, 4th edition","date":"2008","authors2":"","placeOfPublication":"Philadelphia, PA","publisher":"Elsevier"},{"referenceId":11742,"authors":"Mehta J, Wang H, Iqbal SU, Mesa R.","articleTitle":"Epidemiology of myeloproliferative neoplasms in the United States","bookWebsiteJournalTitle":"Leuk. Lymphoma","date":"March 1, 2014","volume":"55(3)","pages":"595-600","url":"http://www.ncbi.nlm.nih.gov/pubmed/23768070","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11743,"authors":"Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA.","articleTitle":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","bookWebsiteJournalTitle":"Eur. J. Haematol.","date":"April 1, 2014","volume":"92(4)","pages":"289-297","url":"http://www.ncbi.nlm.nih.gov/pubmed/24372927","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10801,"questionText":"Is myelofibrosis a rare disorder?","answerText":"According to the definition of a rare disorder per the <a href=\"http://www.fda.gov/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/OrphanDrugAct/\" target=\"_blank\">Orphan Drug act</a>, myelofibrosis is considered a rare disorder given the incidence discussed above.&nbsp;","dateModified":"2016-06-22T17:31:00","references":[]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":2743,"phenoTypeName":"Abnormal megakaryocyte morphology","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":15539,"phenoTypeName":"Anemia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13704,"phenoTypeName":"Fatigue","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8115,"phenoTypeName":"Hepatomegaly","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8125,"phenoTypeName":"Hepatosplenomegaly","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8266,"phenoTypeName":"Pallor","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3886,"phenoTypeName":"Splenomegaly","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":15512,"phenoTypeName":"Thrombocytopenia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13430,"phenoTypeName":"Anorexia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9207,"phenoTypeName":"Arterial thrombosis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":1268,"phenoTypeName":"Bone marrow hypercellularity","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5584,"phenoTypeName":"Easy fatigability","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":12860,"phenoTypeName":"Ecchymosis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13083,"phenoTypeName":"Extramedullary hematopoiesis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":12195,"phenoTypeName":"Flank pain","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13075,"phenoTypeName":"Leukocytosis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":348,"phenoTypeName":"Low-grade fever","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13313,"phenoTypeName":"Lymphadenopathy","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":15515,"phenoTypeName":"Pancytopenia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10294,"phenoTypeName":"Petechiae","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9230,"phenoTypeName":"Poikilocytosis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5701,"phenoTypeName":"Portal hypertension","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":15530,"phenoTypeName":"Thrombocytosis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10903,"phenoTypeName":"Venous thrombosis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":3609,"phenoTypeName":"Cachexia","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":8307,"phenoTypeName":"Hemangioma","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":10335,"phenoTypeName":"Hematological neoplasm","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":2176,"phenoTypeName":"Increased lactate dehydrogenase level","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":13043,"phenoTypeName":"Fever","percentRanges":"-"},{"phenoTypeId":13245,"phenoTypeName":"Myelofibrosis","percentRanges":"-"},{"phenoTypeId":9580,"phenoTypeName":"Myeloproliferative disorder","percentRanges":"-"},{"phenoTypeId":8268,"phenoTypeName":"Purpura","percentRanges":"-"},{"phenoTypeId":8123,"phenoTypeName":"Somatic mutation","percentRanges":"-"}],"medicalProducts":[{"productId":544,"genericName":"Ruxolitinib Phosphate","tradeName":"Jakafi","tradeLink":"http://www.jakafi.com/","manufacturer":"","sponsor":"Incyte Corporation","indication":"Treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.\r\nTreatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=JAKAFI","medlinePlusLink":"http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=56715"}],"EncodedName":"Primary_myelofibrosis"}